Focused On-demand Library for Ribosomal oxygenase 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9H6W3

UPID:

RIOX1_HUMAN

Alternative names:

60S ribosomal protein L8 histidine hydroxylase; Bifunctional lysine-specific demethylase and histidyl-hydroxylase NO66; Myc-associated protein with JmjC domain; Nucleolar protein 66; Ribosomal oxygenase NO66

Alternative UPACC:

Q9H6W3; B4DT02

Background:

Ribosomal oxygenase 1, known for its roles as a histone lysine demethylase and ribosomal histidine hydroxylase, is pivotal in histone code regulation and ribosome biogenesis. It specifically targets 'Lys-4' and 'Lys-36' of histone H3, influencing osteoblast differentiation and non-histone protein functions, such as CGAS demethylation. This protein is also identified by names like 60S ribosomal protein L8 histidine hydroxylase and Nucleolar protein 66.

Therapeutic significance:

Understanding the role of Ribosomal oxygenase 1 could open doors to potential therapeutic strategies.